Showing results (471-480 of 753) with videos related to
Sort By:
Pageof 76
BMC Genomics|February 26, 2010
Correcting for intra-experiment variation in Illumina BeadChip data is necessary to generate robust gene-expression profilesRobert R Kitchen, Vicky S Sabine, Andrew H Sims, et al.Reproduction (Cambridge, England)|May 15, 2009
Effects of active immunization against growth differentiation factor 9 and/or bone morphogenetic protein 15 on ovarian function in cattleJennifer L Juengel, Norma L Hudson, Martin Berg, et al.African Journal of Disability|June 1, 2018
Intellectual disability rights and inclusive citizenship in South Africa: What can a scoping review tell us?Charlotte Capri, Lameze Abrahams, Judith McKenzie, et al.Biology of Reproduction|March 23, 2025
Developmental Programming: Mechanisms of Early Exposure to Real-Life Chemicals in Biosolids on Offspring Ovarian Dynamics†Yiran Zhou, Katherine M Halloran, Michelle Bellingham, et al.Clinical Orthopaedics and Related Research|April 29, 2008
Bisphosphonate delivery to tubular bone allograftsGene R DiResta, Mark W Manoso, Anwar Naqvi, et al.International Archives of Allergy and Immunology|January 22, 2024
Immune Mechanisms Underpinning Long COVID: Collegium Internationale Allergologicum Update 2024Eva Untersmayr, Carina Venter, Peter Smith, et al.Applied Psychophysiology and Biofeedback|August 1, 2023
Utilizing Electromyographic Video Games Controllers to Improve Outcomes for Prosthesis UsersShea McLinden, Peter Smith, Matt Dombrowski, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2005
Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survivalMitch Dowsett, Ian E Smith, Steve R Ebbs, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 16, 2005
Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer--a study from the IMPACT trialistsMitch Dowsett, Steve R Ebbs, J Michael Dixon, et al.Plos One|January 10, 2013
PIK3CA genotype and a PIK3CA mutation-related gene signature and response to everolimus and letrozole in estrogen receptor positive breast cancerSherene Loi, Stefan Michiels, Jose Baselga, et al.Pageof 76